# US 8,541,004 B2 · Composition comprising the polyprotein NS3/NS4 and the polypeptide NS5B of HCV, expression vectors including the corresponding nucleic sequences and their therapeutic use

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 8,541,004 B2
- Document ID: US8541004B2
- Status: Granted
- Kind: B2
- Application number: 13/241,578
- Filed: 2011-09-23
- Published: 2012-02-16
- Granted: 2013-09-24
- Earliest claimed: 2003-06-05
- Assignees: Transgene S.A.
- Applicants: Anne Fournillier; Genevieve Inchauspe; Jean-Daniel Abraham; Maria Dimitrova-Tchomakov; Marie Parnot
- Inventors: Anne Fournillier; Genevieve Inchauspe; Jean-Daniel Abraham; Maria Dimitrova-Tchomakov; Marie Parnot
- Web page: https://patentgrep.com/patent/US8541004B2

## CPC

- C07K 14/005: from viruses
- A61P 1/16: for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
- A61P 31/12: Antivirals
- A61P 31/14: for RNA viruses
- A61P 37/04: Immunostimulants
- A61K 48/00: Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K 2039/525: {Virus}
- A61K 2039/53: {DNA (RNA) vaccination}
- C12N 2710/10343: viral genome or elements thereof as genetic vector
- C12N 2710/24143: viral genome or elements thereof as genetic vector
- C12N 2770/24222: New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)

## Abstract

The invention relates to a peptidic compound containing a polyprotein NS3/NS4 of a hepatitis C virus and a polypeptide NS5b of hepatitis C virus. Said invention also relates to expression vectors such as adenovirus and poxyvirus in which nucleic sequences coding for the polyprotein NS3/NS4 and the polypeptide NS5b. The inventive compound can be used for a therapeutic application.

## Claims

### Claim 1

A peptide composition comprising only two polypeptides originating from one or more hepatitis C virus, wherein one of said polypeptides consists of a full length polyprotein NS3/NS4 of the hepatitis C virus, and wherein the other of said polypeptides consists of a full length polypeptide NS5b of the hepatitis C virus.

### Claim 2 (depends on 1)

The peptide composition according to claim 1, characterized in that NS3 and/or NS4 and/or NS5b originate from viruses of different genotypes.

### Claim 3 (depends on 1)

The peptide composition according to claim 1, characterized in that NS3, NS4 and NS5b originate from a virus of the same genotype.

### Claim 4 (depends on 3)

The composition according to claim 3, wherein said NS3, NS4, and NS5 originate from a virus of genotype 1b.

### Claim 5 (depends on 1, 2, 3)

A pharmaceutical kit:
comprising the composition of claim 1, claim 2 or claim 3.